The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Truxima rituximab Biosimilar | Celltrion Healthcare Hungary Kft. | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Wegener Granulomatosis; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopic Polyangiitis | 🇪🇺 EU 2017-02-17 | Order → |
| Alecensa alectinib Additional monitoring | Roche Registration GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2017-02-16 | Order → |
| Lifmior etanercept | Pfizer Europe MA EEIG | Arthritis, Psoriatic; Spondylitis, Ankylosing; Psoriasis | 🇪🇺 EU 2017-02-13 | Order → |
| Olumiant baricitinib | Eli Lilly Nederland B.V. | Arthritis, Rheumatoid | 🇪🇺 EU 2017-02-13 | Order → |
| Vihuma simoctocog alfa Additional monitoring | Octapharma AB | Hemophilia A | 🇪🇺 EU 2017-02-13 | Order → |
| Cystadrops mercaptamine Orphan | Recordati Rare Diseases | Cystinosis | 🇪🇺 EU 2017-01-18 | Order → |
| Zinplava bezlotoxumab | Merck Sharp & Dohme B.V. | Enterocolitis, Pseudomembranous | 🇪🇺 EU 2017-01-18 | Order → |
| Movymia teriparatide Biosimilar | STADA Arzneimittel AG | Osteoporosis | 🇪🇺 EU 2017-01-11 | Order → |
| Suliqua insulin glargine;lixisenatide | Sanofi Winthrop Industrie | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2017-01-11 | Order → |
| Fiasp insulin aspart | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 2017-01-09 | Order → |
| Talmanco (previously Tadalafil Generics) tadalafil Generic | Viatris Limited | Hypertension, Pulmonary | 🇪🇺 EU 2017-01-09 | Order → |
| Vemlidy tenofovir alafenamide | Gilead Sciences Ireland UC | Hepatitis B | 🇪🇺 EU 2017-01-09 | Order → |
| Afstyla lonoctocog alfa | CSL Behring GmbH | Hemophilia A | 🇪🇺 EU 2017-01-04 | Order → |
| Terrosa teriparatide Biosimilar | Gedeon Richter Plc. | Osteoporosis | 🇪🇺 EU 2017-01-04 | Order → |
| Darunavir Viatris (previously Darunavir Mylan) darunavir Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2017-01-03 | Order → |
| Lusduna insulin glargine Biosimilar | Merck Sharp & Dohme B.V. | Diabetes Mellitus | 🇪🇺 EU 2017-01-03 | Order → |
| Emtricitabine/Tenofovir disoproxil Mylan emtricitabine;tenofovir disoproxil Generic | Mylan Pharmaceuticals Limited | HIV Infections | 🇪🇺 EU 2016-12-16 | Order → |
| Ocaliva obeticholic acid ConditionalAdditional monitoring | Advanz Pharma Limited | Liver Cirrhosis, Biliary | 🇪🇺 EU 2016-12-12 | Order → |
| Rekovelle follitropin delta | Ferring Pharmaceuticals A/S | Anovulation | 🇪🇺 EU 2016-12-12 | Order → |
| Emtricitabine/Tenofovir disoproxil Krka emtricitabine;tenofovir disoproxil Generic | KRKA tovarna zdravil d.d. Novo mesto | HIV Infections | 🇪🇺 EU 2016-12-09 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.